ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "risk and thrombosis"

  • Abstract Number: 379 • 2018 ACR/ARHP Annual Meeting

    Risk Factors of Venous Thromboembolism in Idiopathic Inflammatory Myopathies

    Julien Campagne1, Thomas Moulinet2, Jonathan Epstein3, Sabine Revuz4, Francois Maurier5, Marie-Hélène Schuhmacher6, Philippe Evon7, Alain Meyer8 and Roland Jaussaud2, 1Médecine Interne, Centre Hospitalier Régional Universitaire de Nancy, Vandoeuvre-lès-Nancy, France, 2Médecine Interne, Centre Hospitalier Régional Universitaire de Nancy, Nancy, France, 3Inserm, CIC-1433 Epidémiologie Clinique, Vandoeuvre-lès-Nancy, France, 4Médecine Interne, Hôpitaux Privés de Metz, Metz, France, 5Médecine interne, Hôpitaux Privés de Metz, Metz, France, 6Médecine Interne, Centre Hospitalier Emile Durkheim, Epinal, France, 7Médecine Interne, Centre Hospitalier Jeanne d'Arc, Bar-le-Duc, France, 8Médecine Interne, Centre Hospitalier Régional Universitaire de Strasbourg, Strasbourg, France

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) are heterogeneous disorders characterised by skeletal muscle weakness and muscle inflammation. IIM includes dermatomyositis (DM), polymyositis (PM), antisynthetase syndromes (ASS),…
  • Abstract Number: 2760 • 2017 ACR/ARHP Annual Meeting

    Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking (APS ACTION) Clinical Database and Repository (“Registry”) Analysis: First and Recurrent Thrombosis Risk after 1201 Patient-Years of Follow-up

    Ozan Unlu1, Danieli Andrade2, Alessandra Banzato3, D. Ware Branch4, Paul R. Fortin5, Maria Gerosa6, Roger A. Levy7, Michelle Lopes8, Michelle Petri9, Ignasi Rodriguez10, Maria Tektonidou11, Amaia Ugarte12, Rohan Willis13, Doruk Erkan14 and , on Behalf of APS ACTION .15, 1Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 2Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., Sao Paulo, Brazil, 3Department of Cardiac Thoracic and Vascular Sciences, Clinical Cardiology, Thrombosis Centre, University of Padova, Padova, Italy, 4Obstetrics and Gynecology, University of Utah and Intermountain Healthcare, Salt Lake City, UT, 5Medicine, CHU de Quebec - Universite de Laval, Quebec, QC, Canada, 6Istituto Ortopedico Gaetano Pini, University of Milan, Milano, Italy, 7Rheumatology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, 8Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 9Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, 10Rheumatology, Hospital Clinica, Barcelona, Spain, 11First Department of Internal Medicine, School of Medicine, National University of Athens, Athens, Greece, 12Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Biscay, Spain, 13Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX, 14Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY, 15., New York, NY

    Background/Purpose: APS ACTION Registry was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL)-positive patients with/without other systemic…
  • Abstract Number: 1799 • 2016 ACR/ARHP Annual Meeting

    Smoking, Antiphospholipid Antibodies and Thrombosis in SLE

    Michelle Petri1, George Stojan2 and Wei Fu3, 1Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, 2Rheumatology, Johns Hopkins University, Baltimore, MD, 3Division of Rheumatology, School of Medicine, Johns Hopkins University, Baltimore, MD

    Background/Purpose:   Anticardiolipin Ever smoking 411 (48.1%) Past smoking 246 (49.8%) Current smoking 165 (46.6%) Never smoking 721 (48.9%) P Value (Ever vs. Never) 0.6943…
  • Abstract Number: 1965 • 2016 ACR/ARHP Annual Meeting

    Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking Registry Analysis: First and Recurrent Thrombosis Risk after 720 Patient-Years of Follow-up

    Ozan Unlu1, W. David Branch2, Paul R. Fortin3, Maria Gerosa4, Guillermo J. Pons-Estel5, Maria Tektonidou6, Amaia Ugarte7, Doruk Erkan8 and On Behalf of APS ACTION .9, 1Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 2Obstetrics and Gynecology, University of Utah and Intermountain Healthcare, Salt Lake City, UT, 3Medicine, CHU de Québec - Université Laval, Québec, QC, Canada, 4University of Milan, Istituto Ortopedico Gaetano Pini, Milano, Italy, 5Department of Autoimmune Diseases, Institut Clínic de Medicina i Dermatologia, Hospital Clínic de Barcelona, Barcelona, Spain, 6First Department of Internal Medicine, School of Medicine, National University of Athens, Athens, Greece, 7Hospital Universitario Cruces, Biscay, Spain, 8Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY, 9., New York, NY

    Background/Purpose: APS ACTION Registry was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL)-positive patients. Previously, based on…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology